Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease.
about
Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome?Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionType II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization studyLp-PLA2 Inhibition-The Atherosclerosis Panacea?Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.Niacin: another look at an underutilized lipid-lowering medication.Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice.Inhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations.Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertensionModulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Evaluation of anti-inflammatory activity of selected medicinal plants used in Indian traditional medication system in vitro as well as in vivo.Anti-inflammatory therapeutics for the treatment of atherosclerosis.Darapladib.Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.Evidence for using alpha-lipoic acid in reducing lipoprotein and inflammatory related atherosclerotic risk.Emerging anti-inflammatory drugs for atherosclerosis.Targeting inflammation: impact on atherothrombosis.The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.After FRANCIS: next steps in the clinical evaluation of varespladib methyl.Anti-inflammatory and antioxidant properties of Eriobotrya japonica leaves extracts.Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids.High plasma phospholipase A2 activity, inflammation markers, and LDL alterations in obesity with or without type 2 diabetes.Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.Carboxyethylpyrroles: From Hypothesis to the Discovery of Biologically Active Natural Products.Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?
P2860
Q26853640-2E0B43D8-6549-48E1-8701-55FA43010548Q26997377-E1145EB9-4D68-4FD7-A89B-85FCB328D0EFQ28479244-50824E46-CF69-4799-8B51-23F060ABADCDQ33664272-44B8C43B-DF26-4DA4-8A26-6D9E27204F9AQ34150154-046DA728-A3EA-45E9-B88C-1CB11D92512AQ34255686-9921C43E-D88F-4A97-BFFF-5FA538F743F0Q34422563-59E69BE5-DD20-4044-BE64-6B6BF4FE062EQ34632021-BF2A17D5-B971-4996-85B1-CC034064C0A3Q35540342-C0FA44BA-800A-4973-B377-929A09E31400Q36145180-EE9D6C3A-0230-403F-ADBC-2EE178241CF4Q37346062-066B055A-E523-423F-B007-13586DD14F00Q37626768-87B0EA5D-9708-464D-B3D2-C00C637F2CF8Q37650398-995547BD-7787-4DB1-9B00-4860A692872CQ37658843-E957F870-B5AC-4302-9243-E9D9F2B1932EQ37826117-8B79105F-E716-46AA-BD80-8134AE8FEE57Q38011272-AC0A2DFC-2BB8-4E93-BA5A-3EE2D7967463Q38106998-AF92B414-7772-41BE-8306-AF6AF02F34D4Q38170328-4EAD3C6B-C0C3-4848-98CA-BEE23A50AD0CQ38593722-380AB648-7F74-4540-B334-59F0A9A72465Q38707328-26928D14-1243-4F5C-9CB5-DECBC455E798Q38974307-46602A95-26A0-4B4C-891F-7F9869ED0A3FQ39803214-74052848-FDCB-453C-905D-C8631D6B6D70Q42014702-A55BF978-D51E-4BEA-ACBF-219DF52E3342Q42244528-6AAF4F6D-AA8A-49E3-8B32-DA5E65FA46B9Q43172296-B6A68252-D15A-4E90-AAA9-5F26A9A9399EQ43289695-38AC7A4F-A099-4164-862E-63177BC34156Q49485993-3CC4D460-DBE5-43F4-A903-84A4BB70FC40Q50312729-AE2D3EBD-CDAF-4539-A55A-66F93E282266Q51614577-1AD41C39-2355-4298-B507-9134184FB8FA
P2860
Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Future role for selective phos ...... erotic cardiovascular disease.
@en
Future role for selective phos ...... erotic cardiovascular disease.
@nl
type
label
Future role for selective phos ...... erotic cardiovascular disease.
@en
Future role for selective phos ...... erotic cardiovascular disease.
@nl
prefLabel
Future role for selective phos ...... erotic cardiovascular disease.
@en
Future role for selective phos ...... erotic cardiovascular disease.
@nl
P1476
Future role for selective phos ...... erotic cardiovascular disease.
@en
P2093
Robert S Rosenson
P2860
P304
P356
10.1007/S10557-008-6148-1
P577
2009-01-14T00:00:00Z